Why the study?
Anthracycline-associated cardiotoxicity has substantial impact on morbidity and mortality, making the identification of genetic variants associated with risk clinically important to improve patient care.
What genetic variants are associated with increased risk of anthracycline-associated cardiotoxicity in patients treated for malignancies?
What genetic variants are associated with increased risk of anthracycline-associated cardiotoxicity in patients treated for malignancies?
This review highlights the potential of genetic variants to identify patients at increased risk for anthracycline-associated cardiotoxicity, aiming to improve cardio-oncology care.
Answers are grounded in this paper and cite their sources.
Genetic associations with ACT remain hypothesis-generating; leaves open prospective validation before any clinical risk stratification.
Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated with increased risk of ACT has the potential for significant clinical impact to improve patient care. The goal of this review is to summarize the current evidence supporting genetic variants associated with ACT, identify gaps and limitations in current knowledge, and propose future directions for incorporating genetics into clinical practice for patients treated with anthracyclines. We will discuss mechanisms of ACT that could be illuminated by genetics and discuss clinical applications for the cardiologist/cardio-oncologist.
No takes yet. Share an insight, caveat, or question.
Al-Otaibi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: